Howard McLeod Net Worth

The estimated Net Worth of Howard Mc Leod is at least $27.1 millier dollars as of 17 March 2016. Howard Leod owns over 1,000 units of Cancer Genetics stock worth over $27,060 and over the last 10 years he sold CGIX stock worth over $0. In addition, he makes $0 as Independent Director at Cancer Genetics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Howard McLeod CGIX stock SEC Form 4 insiders trading

Howard has made over 2 trades of the Cancer Genetics stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of CGIX stock worth $2,710 on 17 March 2016.

The largest trade he's ever made was buying 1,000 units of Cancer Genetics stock on 17 March 2016 worth over $2,710. On average, Howard trades about 250 units every 0 days since 2014. As of 17 March 2016 he still owns at least 6,000 units of Cancer Genetics stock.

You can see the complete history of Howard Leod stock trades at the bottom of the page.

Howard McLeod biography

Dr. Howard McLeod, Pharm. D., is the an Independent Director of the Company. Dr. McLeod is a member of our Board and is the Medical Director of the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center, and as a Senior Member of the Moffitt Cancer Center's Division of Population Sciences. He joined Moffitt Cancer Center in September 2013, after having served as a Founding Director of the University of North Carolina Institute for Pharmacogenomics and Individualized Therapy since 2006. Dr. McLeod also held the prestigious title of Fred Eshelman Distinguished Professor at the UNC Eshelman School of Pharmacy from 2006 to 2013. Dr. McLeod has published over 500 peer-reviewed papers on pharmacogenomics, applied therapeutics and clinical pharmacology. He had served as Chief Scientific Advisor and a member of the board of directors of Gentris Corporation before its acquisition by the Company in July 2014 and has served since July 2014 on the Company's Scientific Advisory Board.

How old is Howard McLeod?

Howard McLeod is 51, he's been the Independent Director of Cancer Genetics since 2014. There are 7 older and no younger executives at Cancer Genetics. The oldest executive at Cancer Genetics Inc. is John Pappajohn, 90, who is the Non-Executive Chairman of the Board.

What's Howard McLeod's mailing address?

Howard's mailing address filed with the SEC is 201 NJ-17, Rutherford, NJ 07070, USA.

Insiders trading at Cancer Genetics

Over the last 12 years, insiders at Cancer Genetics have traded over $1,720,897 worth of Cancer Genetics stock and bought 3,891,559 units worth $4,573,241 . The most active insiders traders include John Pappajohn, Tommy G Thompson et John A Roberts. On average, Cancer Genetics executives and independent directors trade stock every 35 days with the average trade being worth of $340,207. The most recent stock trade was executed by John A Roberts on 31 January 2019, trading 185,436 units of CGIX stock currently worth $42,650.

What does Cancer Genetics do?

Complete history of Howard Leod stock trades at Cancer Genetics

Cancer Genetics executives and stock owners

Cancer Genetics executives and other stock owners filed with the SEC include:

• Jane Houldsworth,
  Vice President - Research & Development
• Franklyn Prendergast,
  Independent Director
• Howard McLeod,
  Independent Director
• Edmund Cannon,
  Independent Director
• Thomas Widmann,
  Director
• Geoffrey Harris,
  Director
• John Roberts,
  President, Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer
• John Pappajohn,
  Non-Executive Chairman of the Board
• Panna Sharma,
  Chief Executive Officer
• Raju S.K. Chaganti,
  Director
• Michael J. Welsh,
  Director
• Edward J Sitar,
  Chief Financial Officer
• Igor Gitelman,
  Chief Accounting Officer
• Michael Brian Mc Cartney,
  Chief Commercial Officer
• Michael Glenn Miles,
  Chief Financial Officer
• Ralf Brandt,
  President, Discovery Services
• Rita Shaknovich,
  VP of Hematopathology Services
• Paul Rothman,
  Director
• Keith L Brownlie,
  Director
• Andrew L Pecora,
  Director
• Tommy G Thompson,
  Director
• Steven Hepburn,
  VP of Biopharma Marketing